Adverse Events Following Immunization Associated with Coronavirus Disease 2019 Vaccination Reported in the Mobile Vaccine Adverse Events Reporting System

被引:28
作者
Jeon, Minji [1 ]
Kim, Jehun [2 ]
Oh, Chi Eun [3 ]
Lee, Jin-Young [1 ]
机构
[1] Kosin Univ, Coll Med, Dept Med, Div Infect Dis,Gospel Hosp, 262 Gamcheon Ro, Busan 49267, South Korea
[2] Kosin Univ, Coll Med, Gospel Hosp, Div Pulm & Crit Care Med, Busan, South Korea
[3] Kosin Univ, Coll Med, Dept Pediat, Gospel Hosp, Busan, South Korea
基金
新加坡国家研究基金会;
关键词
COVID-19; Vaccination; Adverse Events Following Immunization; AEFI;
D O I
10.3346/jkms.2021.36.e114
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Vaccination against coronavirus disease 2019 (COVID-19) is underway globally to prevent the infection caused by the severe acute respiratory syndrome coronavirus 2. We aimed to investigate the adverse events following immunization (AEFIs) for COVID-19 among healthcare workers (HCWs). Methods: This was a retrospective study of the AEFIs associated with the first dose of the ChAdOx1 nCoV-19 vaccine at the Kosin University Gospel Hospital from March 3 to March 22, 2021. We investigated the systemic and local adverse events during the 7 days following the vaccination using the Mobile Vaccine Adverse Events Reporting System (MVAERS) developed by our hospital. Results: A total of 1,503 HCWs were vaccinated, and the data of 994 HCWs were reported in the MVAERS. The most commonly reported AEFIs were tenderness at the injection site (94.5%), fatigue (92.9%), pain at the injection site (88.0%), and malaise (83.8%). The severity of most AEFIs was mild-to-moderate, and the severity and number of AEFIs were less in the older age group. There were no serious events requiring hospitalization, and most AEFIs improved within a few days. Conclusion: The AEFIs associated with the ChAdOx1 nCoV-19 vaccine were tolerable, and the use of the MVAERS was helpful in monitoring the AEFIs. The use of MVAERS will help in sharing accurate and ample information about vaccination against COVID-19.
引用
收藏
页码:1 / 8
页数:8
相关论文
共 11 条
[1]   Deep vein thrombosis (DVT) occurring shortly after the second dose of mRNA SARS-CoV-2 vaccine [J].
Carli, Giuseppe ;
Nichele, Ilaria ;
Ruggeri, Marco ;
Barra, Salvatore ;
Tosetto, Alberto .
INTERNAL AND EMERGENCY MEDICINE, 2021, 16 (03) :803-804
[2]  
European Medicines Agency, ASS REP COVID 19 VAC
[3]   COVID-19 Vaccination and the Challenge of Infodem'c and Disinformation [J].
Farooq, Fareeha ;
Rathore, Farooq Azam .
JOURNAL OF KOREAN MEDICAL SCIENCE, 2021, 36 (10) :1-4
[4]   Estimating Baseline Incidence of Conditions Potentially Associated with Vaccine Adverse Events: a Call for Surveillance System Using the Korean National Health Insurance Claims Data [J].
Huh, Kyungmin ;
Kim, Young-Eun ;
Radnaabaatar, Munkhzul ;
Lee, Dae Ho ;
Kim, Dong Wook ;
Shin, Soon-Ae ;
Jung, Jaehun .
JOURNAL OF KOREAN MEDICAL SCIENCE, 2021, 36 (09) :e67
[5]  
Korea Centers for Disease Control and Prevention, COVID 19 DOM OCC VAC
[6]  
Lee K, 2009, GLOB INST, P1
[7]   Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine [J].
Polack, Fernando P. ;
Thomas, Stephen J. ;
Kitchin, Nicholas ;
Absalon, Judith ;
Gurtman, Alejandra ;
Lockhart, Stephen ;
Perez, John L. ;
Perez Marc, Gonzalo ;
Moreira, Edson D. ;
Zerbini, Cristiano ;
Bailey, Ruth ;
Swanson, Kena A. ;
Roychoudhury, Satrajit ;
Koury, Kenneth ;
Li, Ping ;
Kalina, Warren V. ;
Cooper, David ;
Frenck, Robert W., Jr. ;
Hammitt, Laura L. ;
Tureci, Ozlem ;
Nell, Haylene ;
Schaefer, Axel ;
Unal, Serhat ;
Tresnan, Dina B. ;
Mather, Susan ;
Dormitzer, Philip R. ;
Sahin, Ugur ;
Jansen, Kathrin U. ;
Gruber, William C. .
NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (27) :2603-2615
[8]   AZD1222 (Covishield) vaccination for COVID-19: Experiences, challenges, and solutions in Nepal [J].
Sah, Ranjit ;
Shrestha, Sunil ;
Mehta, Rachana ;
Sah, Sohan Kumar ;
Rabaan, Ali A. ;
Dhama, Kuldeep ;
Rodriguez-Morales, Alfonso J. .
TRAVEL MEDICINE AND INFECTIOUS DISEASE, 2021, 40
[9]  
Shimabukuro T, 2021, MMWR-MORBID MORTAL W, V70, P46, DOI [10.1111/ajt.16516, 10.15585/mmwr.mm7004e1externalicon]
[10]  
U.S. Food & Drug Administration, TOX GRAD SCAL HLTH A